MSS
Maison Solutions Inc. Class A Common Stock·Consumer Defensive
0.96
0.724%(+0.01)
Close PriceLast Updated: — ET
52W L: $0.9252W H: $39.60
MSS NEWS
accessnewswire.com
2d ago
Alexandria Marie Lopez of Maison Solutions Inc. Named 2026 LA Executive Awards Nominee
MONTEREY PARK, CA / ACCESS Newswire / May 25, 2026 / Maison Solutions Inc. (NASDAQ:MSS) ("Maison Solutions" or the "Company"), a specialty grocery retailer offering traditional Asian food and merchandise to customers in the United States, today announced that Alexandria Marie Lopez, Chief Financial Officer, has been named a 2026 nominee for the LA Executive Awards, presented by LA Times Studios and the Los Angeles Times Media Group. The LA Executive Forum & Leadership Awards brings together executives and entrepreneurs from the Los Angeles region for networking, strategic discussions, and recognition.
accessnewswire.com
May 12
Maison Solutions Inc. Regains Compliance with Nasdaq Minimum Bid Price Requirement
MONTEREY PARK, CA / ACCESS Newswire / May 12, 2026 / Maison Solutions Inc. (NASDAQ:MSS) ("Maison Solutions" or the "Company"), a specialty grocery retailer offering traditional Asian food and merchandise to U.S. consumers, today announced that on May 11, 2026, it received written notification from The Nasdaq Listing Qualifications Department of the Nasdaq Stock Market LLC stating that the Company has regained compliance with the $1.00 minimum bid price requirement set forth in Nasdaq Listing Rule 5550(a)(2) for continued listing on the Nasdaq Capital Market. Accordingly, the Company's Class A common stock will continue to be listed and traded on the Nasdaq Capital Market.
prnewswire.com
May 10
Innovent Announces IBI363 (PD-1/IL-2α-bias Bispecific Fusion Protein) Received Third NMPA Breakthrough Therapy Designation for MSS/pMMR Metastatic Colorectal Cancer
SAN FRANCISCO and SUZHOU, China, May 10, 2026 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic, ophthalmology, and other major diseases, announced that the Center for Drug Evaluation (CDE) of China's National Medical Products Administration (NMPA) has granted a third Breakthrough Therapy Designation (BTD) to its first-in-class PD-1/IL-2α-bias bispecific fusion protein, IBI363, in combination with bevacizumab, for the treatment of patients with advanced microsatellite stable or proficient mismatch repair (MSS/pMMR) colorectal cancer (CRC) who have failed at least two prior lines of standard therapy. A Phase III clinical trial is about to initiate in China for this indication in the near term.
globenewswire.com
May 4
Oncolytics Biotech® Reports Durable Responses in Second-Line RAS-Mutant MSS Colorectal Cancer
2L KRAS-Mutant MSS mCRC Demonstrates ~3–4x Improvement in Duration of Response vs. Historical 4–6 Month Benchmark Company Engaged with FDA to Support Potential Accelerated Approval Pathway in 2L RAS-Mutant MSS mCRC SAN DIEGO, May 04, 2026 (GLOBE NEWSWIRE) -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (“Oncolytics” or the “Company”), a clinical-stage company developing pelareorep, an investigational, systemically delivered immunotherapy that has been shown to activate innate immune-sensing pathways, today announced new durability data in metastatic colorectal cancer (“mCRC”), demonstrating meaningful and sustained clinical benefit in patients with RAS-mutant, microsatellite-stable (“MSS”) disease.
accessnewswire.com
Apr 29
Notice of Proposed Settlement of Stockholder Derivative Action: Maison Solutions Inc.
MONTEREY PARK, CA / ACCESS Newswire / April 29, 2026 / Maison Solutions Inc. (NASDAQ:MSS) today provided notice of proposed settlement of derivative actions and settlement hearing. UNITED STATES DISTRICT COURT CENTRAL DISTRICT OF CALIFORNIA IN RE MAISON SOLUTIONS INC.
globenewswire.com
Apr 29
Notice of Proposed Settlement of Stockholder Derivative Action: Maison Solutions Inc.
MONTEREY PARK, Calif., April 29, 2026 (GLOBE NEWSWIRE) -- Maison Solutions Inc. (NASDAQ:MSS) today provided notice of proposed settlement of derivative actions and settlement hearing.
